QX-004N

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameQX-004N
Drug Alias Name重组人源化抗IL-23单克隆抗体注射液QX-004NHS-20137
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Interleukin-23 subunit p19
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQyuns Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHansen (Shanghai) Health Technology Co LtdHansoh Pharmaceutical Group Company LtdQyuns Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A